The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 17, 2025
Filed:
Oct. 23, 2024
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Eric Furfine, Concord, MA (US);
Daniel Dix, LaGrangeville, NY (US);
Kenneth Graham, Pleasant Valley, NY (US);
Kelly Frye, Mendham, NJ (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61M 5/178 (2006.01); C07K 14/47 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
C07K 14/71 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/19 (2013.01); A61K 38/179 (2013.01); A61K 38/1793 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61M 5/178 (2013.01); C07K 14/47 (2013.01); C07K 14/4705 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01);
Abstract
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.